Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cellgram-DC-WT1
- Development stage
- Phase 2
- Lead developer
- Pharmicell
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Intradermal
01
Overview
Cellgram-DC-WT1 is an autologous dendritic cell-based immunotherapy developed by Pharmicell. It consists of a patient's own dendritic cells that are harvested, matured, and pulsed with Wilms' Tumor 1 (WT1) antigens. WT1 is a zinc-finger transcription factor that is highly overexpressed in various hematological malignancies and solid tumors but has limited expression in normal adult tissues, making it an ideal target for cancer vaccines. Once re-infused into the patient, these antigen-presenting cells migrate to the lymph nodes where they activate and expand WT1-specific CD8+ cytotoxic T lymphocytes and CD4+ helper T cells. This coordinated immune response is designed to identify and eliminate residual cancer cells, particularly in the context of preventing relapse in patients with acute myeloid leukemia (AML).
- Brand names
- Cellgram-DC-WT1Cellgram-DC-WT-1Cellgram-DC-WT 1
- Other names
- WT1-pulsed dendritic cell vaccineWT-1-pulsed dendritic cell vaccineWT 1-pulsed dendritic cell vaccinePharmicell dendritic cell vaccine
02
Targets
WT1 (Wilms tumor protein)
Beyond the preview
Go deeper on Cellgram-DC-WT1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cellgram-DC-WT1.